The Week in Health: Novartis to Invest US$9.7 billion in Acquisition
Home > Health > Weekly Roundups

The Week in Health: Novartis to Invest US$9.7 billion in Acquisition

Share it!
Miriam Bello By Miriam Bello | Senior Journalist and Industry Analyst - Fri, 11/29/2019 - 12:16

The Mexican healthcare sector welcomes the changes made by the new administration as challenges to their efficiency keep showing. Meanwhile, Novartis’ expansion in its drug portfolio would put the company in a much better position as a pharmaceutical giant.

Ready for more? This is the Week in Health!


COFEPRIS to release a list of foods, supplements, alcoholic and non-alcoholic beverages, medications and drugs that must be withdrawn from the market for representing risks or damages to the population’s health.

To provide better care for patients, the National Union of Health Workers will seek better benefits for health professionals.

Problems on the health sector’s official websites are highlighted in a study made by Ibero and Data Lab Mx. Mistrust, disinformation and lack of transparency are some of the things that these mistakes create.

Coahuila’s lack of proper medical services is evident as patients are infected with diseases at healthcare facilities.


The multinational Novartis will buy The Medicine Company, a biotech firm that focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower the so-called bad cholesterol. This US$9.7 billion acquisition would lead to an expansion in Novartis’ drug portfolio.

The Argentinian president is using abortion debate as a reelection campaign strategy. He stands by his conservative posture against the legalization of this practice.

New Zealand, a pioneer in HIV positive sperm donation. Donors of this sperm bank are carriers of the HIV virus but cannot transmit it.

You May Like

Most popular